Abstract
TRAIL, the ligand for the newly discovered DR-4 and DR-5 receptor, is a member of the TNF family of death signal transduction proteins with a mechanism of cell death similar to that of Fas and Fas ligand (Fas-L) system. We provide first time evidence that TRAIL is a potent inducer of apoptosis in multiple myeloma (MM) cell lines. TRAIL effectively induced extensive apoptosis in 8226 and ARP-1 MM cells in a time- and dose-dependent manner. Apoptosis with TRAIL reached about 80% within 48 h of treatment with a dose of 160 ng/ml. Furthermore, we provide first time evidence that similar to Fas, TRAIL-induced apoptosis is not blocked by bcl-2 in MM cell lines. Most importantly, TRAIL induced substantial apoptosis in freshly isolated, flow-sorted myeloma cells obtained from different MM patients expressing variable levels of bcl-2. Finally, we demonstrate for the first time that TRAIL is not cytotoxic to purified CD34+/CD45dim hematopoietic stem cells and does not inhibit CFU-GM or BFU-E colony formation in methylcellulose.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
SCARA3 inhibits cell proliferation and EMT through AKT signaling pathway in lung cancer
BMC Cancer Open Access 16 May 2022
-
Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey
Cell Death & Disease Open Access 11 August 2016
-
Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy
Scientific Reports Open Access 20 December 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gazitt, Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 13, 1817–1824 (1999). https://doi.org/10.1038/sj.leu.2401501
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401501
Keywords
This article is cited by
-
Aponermin: First Approval
Drugs (2024)
-
SCARA3 inhibits cell proliferation and EMT through AKT signaling pathway in lung cancer
BMC Cancer (2022)
-
Oncolytic viruses: emerging options for the treatment of breast cancer
Medical Oncology (2017)
-
Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey
Cell Death & Disease (2016)
-
Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy
Scientific Reports (2013)